Aurigene Discovery Technologies Limited

27 articles with Aurigene Discovery Technologies Limited

• Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

  7/5/2022

  The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.

• Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

  6/9/2022

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an exclusive global license agreement to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.

• Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

  10/14/2021

  Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today announced that Exelixis has exercised its exclusive option under the companies’ July 2019 agreement to in-license XL114

• Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor

  10/9/2020

  Detailed characterization of an oral inhibitor of CDK7 demonstrates potent activity against multiple hematologic and solid tumor cell lines, as monotherapy and in combination with chemotherapies

• Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

  7/31/2019

  Companies will partner to advance small molecules in up to six discrete projects, including three existing programs against specific predetermined targets

• Aurigene Announces First in Human Dosing with RoRγt Inverse Agonist AUR-101

  7/11/2018

  Phase 1 data from the study expected to be available by December 2018

• Curis Announces FDA Fast Track Designation for Fimepinostat (CUDC-907) Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  5/31/2018

  Curis, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of fimepinostat in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

• Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

  5/24/2018

  Curis, Inc. today announced that Robert Martell, M.D., Ph.D., has been appointed Head of Research and Development.

• Aurigene Discovery Technologies Limited, A Wholly Owned Subsidiary Of Dr. Reddy's Laboratories Ltd.’s, And Curis Announce CA-170 Program Update Following Data Presented At ESMO 2017

  9/12/2017

• Curis And Aurigene Discovery Technologies Limited Announce CA-170 Program Update Following Data Presented At ESMO 2017

  9/11/2017

• Agios And Aurigene Discovery Technologies Limited Enter Into Exclusive License Agreement For Novel Small Molecules For Cancer Metabolism Target

  4/27/2017

• Aurigene Discovery Technologies Limited Announces The Exercise Of Curis' Option For CA-327 (PD-L1/TIM-3 Small Molecule Antagonist), The Third Program Under Its Collaboration, License And Option Agreement Of January, 2015 (October 11, 2016, New Jersey, NJ,

  10/11/2016

• Curis And Aurigene Discovery Technologies Limited Present Preclinical Data From Multiple Programs At AACR Annual Meeting

  4/20/2016

• Aurigene Discovery Technologies Limited To Present Its CDK7 And KRAS Covalent Inhibitor Programs At AACR Annual Conference

  4/15/2016

• Aurigene Discovery Technologies Limited To Present Its CDK7, Dual PD-1/VISTA And IRAK4 Inhibitor Programs At AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics (November 5-9, Boston, MA)

  11/3/2015

• Curis, Inc., Aurigene Discovery Technologies Limited Forge $415 Million+ Immuno-Oncology Pact

  1/22/2015

• Aurigene Discovery Technologies Limited And Orion Corporation Announce Research, Collaboration And Option Agreement For Rights To Aurigene's Epigenetics Program For Pan BET And Selective BET Bromodomain Inhibitors

  6/24/2014

• Aurigene Discovery Technologies Limited And Pierre Fabre Announce A Licensing Agreement For A New Cancer Therapeutic In Immuno-Oncology : AUNP12, An Immune Checkpoint Modulator Targeting The PD-1 Pathway

  2/12/2014

• Aurigene Discovery Technologies Limited and Debiopharm Group&#0153 Report Nomination of Development Candidate Debio 0617B in Oncology

  6/20/2013

• Aurigene Discovery Technologies Limited and Debiopharm Report Nomination of Development Candidate Debio 0617B in Oncology

  6/19/2013